ERASER研究:新一代机械取栓装置与虚拟对照比较
主要终点为通过机器学习模型基于静脉tPA患者数据预测的梗死体积与实际梗死体积之差(挽救组织体积)。结果显示实际梗死体积小于预测值,中位挽救组织体积50 mL(IQR 19-103,P<0.0001),90天良好临床结局(mRS 0-2)48/69(70%),再通率(TICI 2b/3)95%。
要点
- 新一代取栓装置联合中间导管治疗大血管闭塞卒中,实际梗死体积小于静脉tPA模型预测值。
- 中位挽救组织体积为50 mL(IQR 19-103,P<0.0001)。
- 90天良好临床结局(mRS 0-2)达70%(48/69),再通率(TICI 2b/3)为95%。
核心结论
- 新一代机械取栓方法使梗死体积小于单纯静脉tPA治疗的预测值,并显示高比例的良好临床结局。
研究设计与样本
- 主要终点为挽救组织体积,即实际梗死体积与基于静脉tPA患者数据的机器学习模型预测梗死体积之差。
主要发现
- 实际梗死体积小于静脉tPA模型预测值,中位挽救组织体积为50 mL(IQR 19-103,P<0.0001)。
- 90天良好临床结局(mRS 0-2)见于48/69例(70%)。
- 再通率(TICI 2b/3)为95%。
临床怎么用
- 该研究提示基于预测分析的虚拟对照设计可用于评估取栓装置,并支持新一代取栓装置联合中间导管可减小梗死体积并提高良好结局比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Using a novel study design with virtual comparators based on predictive modeling, we investigated whether next-generation mechanical thrombectomy devices improve outcomes in patients with ischemic stroke. We hypothesized that this new study design shows that a next-generation mechanical thrombectomy system is superior to intravenous tPA (tissue-type plasminogen activator) therapy (IVT) alone. Methods- ERASER (Eric Acute Stroke Recanalization) was an investigator-initiated, prospective, multicenter, single-arm (virtual 2-arm) study that evaluated the effectiveness of a new recanalization device together with a specific intermediate catheter (Embolus Retriever with Interlinked Cages/SOFIA, Microvention) in stroke patients with internal carotid artery or middle cerebral artery occlusions. The primary end point was the volume of saved tissue. Volume of saved tissue was defined as the difference of actual infarct volume and brain volume predicted to develop infarction using a machine learning model based on data from intravenous tPA therapy patients. Results- Eighty-one patients were enrolled. The median patient age was 71 years (interquartile range, 61-77). National Institutes of Health Stroke Scale score was 14 (interquartile range, 12-18). The actual infarct volume was smaller than predicted by the intravenous tPA therapy model, with a median volume of saved tissue of 50 mL (interquartile range, 19-103; P<0.0001). Good clinical outcome (modified Rankin Scale, 0-2 at 90 days) was observed in 48 out of 69 (70%). The recanalization rate (Thrombolysis in Cerebral Infarction 2b/3) was 95%. Conclusions- ERASER is the first mechanical thrombectomy study with a primary end point based on predictive analytics enabling intraindividual virtual comparisons. The next-generation mechanical thrombectomy method resulted in smaller infarcts than predicted after intravenous tPA therapy alone and showed a high rate of good clinical outcome. The novel study design with virtual comparisons is promising for further application and testing in the neurovascular arena. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02534701.
引用
- Fiehler J, Thomalla G, Bernhardt M, et al. ERASER. Stroke. 2019. PMID: 31009356. doi:10.1161/STROKEAHA.119.024858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。